$1.16
4.13% day before yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US95075A1079
Symbol
HOWL

Werewolf Therapeutics Inc Stock price

$1.16
+0.11 10.48% 1M
-0.21 15.33% 6M
-0.32 21.62% YTD
-1.14 49.57% 1Y
-3.45 74.84% 3Y
-14.94 92.80% 5Y
-14.94 92.80% 10Y
-14.94 92.80% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.05 4.13%
ISIN
US95075A1079
Symbol
HOWL
Industry

Key metrics

Basic
Market capitalization
$52.1m
Enterprise Value
$-13.4m
Net debt
positive
Cash
$92.0m
Shares outstanding
44.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
45.7 | -
EV/Sales
negative | -
EV/FCF
0.2
P/B
0.9
Financial Health
Equity Ratio
57.8%
Return on Equity
-96.1%
ROCE
-78.5%
ROIC
-
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$1.1m | $0.0
EBITDA
$-73.2m | $-89.4m
EBIT
$-75.0m | $-89.1m
Net Income
$-72.4m | $-81.1m
Free Cash Flow
$-60.0m
Growth (TTM | estimate)
Revenue
-93.0% | -100.0%
EBITDA
-67.7% | -24.5%
EBIT
-65.0% | -21.1%
Net Income
-74.1% | -15.0%
Free Cash Flow
-54.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-6,404.2% | -
EBIT
-6,559.6%
Net
-6,335.2% | -
Free Cash Flow
-5,247.8%
More
EPS
$-1.6
FCF per Share
$-1.3
Short interest
3.3%
Employees
45
Rev per Employee
$40.0k
Show more

Is Werewolf Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

Werewolf Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Werewolf Therapeutics Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Werewolf Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Werewolf Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.14 1.14
93% 93%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
1% 1%
1,660%
- Research and Development Expense 57 57
32% 32%
4,969%
-73 -73
68% 68%
-6,421%
- Depreciation and Amortization 1.78 1.78
1% 1%
156%
EBIT (Operating Income) EBIT -75 -75
65% 65%
-6,577%
Net Profit -72 -72
74% 74%
-6,352%

In millions USD.

Don't miss a Thing! We will send you all news about Werewolf Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Werewolf Therapeutics Inc Stock News

Neutral
GlobeNewsWire
25 days ago
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical...
Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D.
Neutral
GlobeNewsWire
2 months ago
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer an...
More Werewolf Therapeutics Inc News

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Dan Hicklin
Employees 45
Founded 2017
Website werewolftx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today